DE3707652A1 - Use of benzo[de]isoquinoline-1,3-diones for preparing pharmaceuticals - Google Patents
Use of benzo[de]isoquinoline-1,3-diones for preparing pharmaceuticalsInfo
- Publication number
- DE3707652A1 DE3707652A1 DE19873707652 DE3707652A DE3707652A1 DE 3707652 A1 DE3707652 A1 DE 3707652A1 DE 19873707652 DE19873707652 DE 19873707652 DE 3707652 A DE3707652 A DE 3707652A DE 3707652 A1 DE3707652 A1 DE 3707652A1
- Authority
- DE
- Germany
- Prior art keywords
- group
- acid
- alkylamino
- isoquinoline
- benzo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- XJHABGPPCLHLLV-UHFFFAOYSA-N benzo[de]isoquinoline-1,3-dione Chemical class C1=CC(C(=O)NC2=O)=C3C2=CC=CC3=C1 XJHABGPPCLHLLV-UHFFFAOYSA-N 0.000 title claims abstract description 6
- 239000003814 drug Substances 0.000 title 1
- 201000010099 disease Diseases 0.000 claims abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 3
- 230000003612 virological effect Effects 0.000 claims abstract description 3
- -1 amino- Chemical class 0.000 claims description 9
- 125000003282 alkyl amino group Chemical group 0.000 claims description 4
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 150000007513 acids Chemical class 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 125000003277 amino group Chemical group 0.000 claims description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 2
- 125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000004953 trihalomethyl group Chemical group 0.000 claims description 2
- 239000003826 tablet Substances 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000701822 Bovine papillomavirus Species 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 241000709691 Enterovirus E Species 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 241000711970 Vesiculovirus Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229940045996 isethionic acid Drugs 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical compound NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
- 239000007885 tablet disintegrant Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/14—Aza-phenalenes, e.g. 1,8-naphthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
Abstract
Description
Es ist bereits bekannt, daß eine Benzo[de]isochinolin-1,3-dione eine Wirkung gegen Viren besitzen (Chemotherapy 25, 83 (1979), Arch. Virol. 74, 157 (1982), Antiviral Research 4, 201 (1984), JP-OS 79/160 127 (Chem. Abstr. 93, 2247e (1980)). Die Wirkung dieser Verbindungen ist jedoch nicht in jeder Hinsicht befriedigend.It is already known that a benzo [de] isoquinoline-1,3-dione is a Possess activity against viruses (Chemotherapy 25, 83 (1979), Arch. Virol. 74, 157 (1982), Antiviral Research 4, 201 (1984), JP-OS 79/160 127 (Chem. Abstr. 93, 2247e (1980)). However, the effect of these compounds is not satisfactory in every way.
Es wurde nun gefunden, daß eine Reihe von Benzo[de]isochinolin-1,3-dionen eine bessere antivirale Wirkung besitzen.It has now been found that a number of benzo [de] isoquinoline-1,3-diones have a better antiviral effect.
Gegenstand der Erfindung ist die Verwendung von Benzo[de]isochinolin-1,3-dionen der Formel IThe invention relates to the use of Benzo [de] isoquinoline-1,3-diones of the formula I
worinwherein
Xeine Nitro-, C1-4-Alkylamino-, Di-C1-4-alkylamino-, Hydroxy, C1-4-Alkoxy-, Trihalogenmethyl-, C1-4-Alkyl-, Formyl-, C1-4-Alkylcarbonyl, C1-5-Acylamino- oder C1-4-Alkoxycarbonylaminogruppe oder ein Halogenatom und Yeine Amino-, C1-4-Alkylamino-, Di-C1-4-alkylamino-, Pyrrolidino-, Piperidino-, Morpholino- oder Piperazinogruppen und ndie Zahlen 0, 1, 2, 3 oder 4Xeine nitro, C 1-4 alkylamino, di-C 1-4 alkylamino, hydroxy, C 1-4 alkoxy, trihalomethyl, C 1-4 alkyl, formyl, C 1-4 -Alkylcarbonyl, C 1-5 -acylamino or C 1-4 -alkoxycarbonylamino group or a halogen atom and Yeine amino-, C 1-4 -alkylamino-, di-C 1-4 -alkylamino-, pyrrolidino-, piperidino-, morpholino - or piperazino groups and n the numbers 0, 1, 2, 3 or 4
darstellen, wobei jedoch n ungleich 2 ist, wenn a) X eine Nitrogruppe und Y eine Dimethylamino- oder Pyrrolidinogruppe oder b) X eine Aminogruppe und Y eine Dimethylaminogruppe ist, sowie deren Salzen mit physikalisch verträglichen Säuren bei der Bekämpfung von viralen Erkrankungen. represent, however, n is not equal to 2 if a) X is a nitro group and Y is a dimethylamino or pyrrolidino group or b) X is an amino group and Y is a dimethylamino group, and their salts with physically compatible acids in combating viral diseases.
Die Verbindungen der Formel I sind aus der US-PS 42 04 063 und der DE-OS 23 23 555 bekannt, wo auch ihre Herstellung beschrieben ist. Als physiologisch verträgliche Säuren eignen sich zur Salzbildung organische und anorganische Säuren, wie Salzsäure, Schwefelsäure, Phosphorsäure, Essigsäure, Zitronensäure, Oxalsäure, Malonsäure, Salicylsäure, Maleinsäure, Fumarsäure, Bernsteinsäure, Ascorbinsäure, Apfelsäure, Methansulfonsäure, Isethionsäure, Milchsäure, Gluconsäure, Glucuronsäure, Amidosulfonsäure, Benzoesäure, Weinsäure, Pamoasäure.The compounds of formula I are from US-PS 42 04 063 and DE-OS 23 23 555 known where its manufacture is described. As Physiologically acceptable acids are suitable for salt formation and inorganic acids, such as hydrochloric acid, sulfuric acid, phosphoric acid, Acetic acid, citric acid, oxalic acid, malonic acid, salicylic acid, Maleic acid, fumaric acid, succinic acid, ascorbic acid, malic acid, Methanesulfonic acid, isethionic acid, lactic acid, gluconic acid, glucuronic acid, Amidosulfonic acid, benzoic acid, tartaric acid, pamoic acid.
Die Verbindungen der Formel I eignen sich insbesondere zur Behandlung von Infektionen, die durch DNA-Viren, z. B. Papillomaviren, Adenoviren, Herpesviren, und RNA-Viren, z. B. Enteroviren, Rhinoviren, Influenzaviren, Vesiculoviren, hervorgerufen werden. Sie werden normalerweise in einer Menge von 25 mg bis 300 mg bei oraler Gabe und von 20 mg bis 250 mg bei parenteraler Gabe appliziert.The compounds of formula I are particularly suitable for the treatment of Infections caused by DNA viruses, e.g. B. papilloma viruses, adenoviruses, Herpes viruses, and RNA viruses, e.g. B. enteroviruses, rhinoviruses, influenza viruses, Vesiculoviruses are caused. They are usually in one Amount of 25 mg to 300 mg with oral administration and from 20 mg to 250 mg with parenteral administration.
Die Verbindungen der Formel I können in üblicher Weise oral oder parenteral verabfolgt werden. Sie können in den gebräuchlichen galenischen Applikationsformen fest oder flüssig angewendet werden, z. B. als Tabletten, Filmtabletten, Kapseln, Granulate, Dragees oder Lösungen. Diese werden in üblicher Weise hergestellt. Die Wirkstoffe können dabei mit den üblichen galenischen Hilfsmitteln, wie Tablettenbindern, Füllstoffen, Konservierungsmitteln, Tablettensprengmitteln, Fließregulierungsmitteln, Weichmachern, Netzmitteln, Dispergiermitteln, Emulgatoren, Lösungsmitteln, Retadierungsmitteln und/oder Antioxidaten verarbeitet werden (vgl. H. Sucker et al: Pharmazeutische Technologie, Thieme-Verlag, Stuttgart, 1978). Die so erhaltenen Applikationsformen enthalten den Wirkstoff normalerweise in einer Menge von 10 bis 90 Gew.-%. The compounds of formula I can be administered orally or in the usual way administered parenterally. You can use the galenic in common Application forms can be used in solid or liquid form, e.g. B. as Tablets, film-coated tablets, capsules, granules, dragees or solutions. These are manufactured in the usual way. The active ingredients can with the usual pharmaceutical auxiliaries, such as tablet binders, fillers, Preservatives, tablet disintegrants, flow regulators, Plasticizers, wetting agents, dispersing agents, emulsifiers, solvents, Retardants and / or antioxidants are processed (cf. H. Sucker et al: Pharmaceutical Technology, Thieme-Verlag, Stuttgart, 1978). The application forms thus obtained contain the active ingredient usually in an amount of 10 to 90% by weight.
Zur Behandlung viraler Infekte eignen sich beispielsweise folgende Substanzen der Formel I:For example, the following are suitable for the treatment of viral infections Substances of formula I:
Auf einer Tablettenpresse werden in üblicher Weise Tabletten folgender Zusammensetzung gepreßt:On a tablet press, tablets are as follows in the usual way Composition pressed:
100 mg Substanz Nr. 1
120 mg Maisstärke
13,5 mg Gelatine
45 mg Milchzucker
2,25 mg Aersosil® (chemisch reine Kieselsäure in submikroskopisch feiner Verteilung)
6,75 mg Kartoffelstärke (als 6%iger Kleister)100 mg of substance No. 1
120 mg corn starch
13.5 mg gelatin
45 mg milk sugar
2.25 mg Aersosil® (chemically pure silica in submicroscopic fine distribution)
6.75 mg potato starch (as 6% paste)
In üblicher Weise werden Dragees folgender Zusammensetzung hergestellt:Coated tablets of the following composition are produced in the usual way:
25 mg Substanz Nr.12
60 mg Kernmasse
60 mg Verzuckerungsmasse25 mg substance no.12
60 mg core mass
60 mg saccharification mass
Die Kernmasse besteht aus 9 Teilen Maisstärke, 3 Teilen Milchzucker und 1 Teil Luviskol® VA 64 (Vinylpyrrolidon-Vinylacetat-Mischpolymerisat 60 : 40, vgl. Pharm. Ind. 1962, 586). Die Verzuckerungsmasse besteht aus 5 Teilen Rohrzucker, 2 Teilen Maisstärke, 2 Teilen Calciumcarbonat und 1 Teil Talk. Die so hergestellten Dragees werden anschließend mit einem magensaftresistenten Überzug versehen.The core consists of 9 parts of corn starch, 3 parts of milk sugar and 1 Part of Luviskol® VA 64 (vinyl pyrrolidone / vinyl acetate copolymer 60: 40, cf. Pharm. Ind. 1962, 586). The saccharification mass consists of 5 Parts of cane sugar, 2 parts of corn starch, 2 parts of calcium carbonate and 1 part talk. The coated tablets produced in this way are then mixed with a enteric enteric coating.
20 g Substanz Nr. 72 werden in 5000 ml Wasser unter Zusatz von NaCl gelöst und mit 0,1 N NaOH auf pH 6,0 eingestellt, so daß eine blutisotonische Lösung entsteht. Jeweils 5 ml dieser Lösung werden in Ampullen gefüllt und sterilisiert.20 g of substance No. 72 are in 5000 ml of water with the addition of NaCl dissolved and adjusted to pH 6.0 with 0.1 N NaOH, so that a blood isotonic solution arises. Each 5 ml of this solution are in Ampoules filled and sterilized.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19873707652 DE3707652A1 (en) | 1987-03-10 | 1987-03-10 | Use of benzo[de]isoquinoline-1,3-diones for preparing pharmaceuticals |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19873707652 DE3707652A1 (en) | 1987-03-10 | 1987-03-10 | Use of benzo[de]isoquinoline-1,3-diones for preparing pharmaceuticals |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE3707652A1 true DE3707652A1 (en) | 1988-09-22 |
Family
ID=6322687
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19873707652 Withdrawn DE3707652A1 (en) | 1987-03-10 | 1987-03-10 | Use of benzo[de]isoquinoline-1,3-diones for preparing pharmaceuticals |
Country Status (1)
| Country | Link |
|---|---|
| DE (1) | DE3707652A1 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991007965A1 (en) * | 1989-11-29 | 1991-06-13 | Knoll Aktiengesellschaft | Mitonaphide infusion solution |
| WO1998017278A1 (en) * | 1996-10-21 | 1998-04-30 | Allelix Biopharmaceuticals Inc. | Neurotrophin antagonist compositions |
| US6468990B1 (en) | 1999-05-17 | 2002-10-22 | Queen's University At Kingston | Method of inhibiting binding of nerve growth factor to p75 NTR receptor |
| US6492380B1 (en) | 1999-05-17 | 2002-12-10 | Queen's University At Kingston | Method of inhibiting neurotrophin-receptor binding |
| US7579468B2 (en) | 2005-09-15 | 2009-08-25 | Painceptor Pharma Corporation | Methods of modulating neurotrophin-mediated activity |
-
1987
- 1987-03-10 DE DE19873707652 patent/DE3707652A1/en not_active Withdrawn
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991007965A1 (en) * | 1989-11-29 | 1991-06-13 | Knoll Aktiengesellschaft | Mitonaphide infusion solution |
| WO1998017278A1 (en) * | 1996-10-21 | 1998-04-30 | Allelix Biopharmaceuticals Inc. | Neurotrophin antagonist compositions |
| US7291629B2 (en) | 1996-10-21 | 2007-11-06 | Painceptor Pharma Corporation | Neurotrophin antagonist compositions |
| US6468990B1 (en) | 1999-05-17 | 2002-10-22 | Queen's University At Kingston | Method of inhibiting binding of nerve growth factor to p75 NTR receptor |
| US6492380B1 (en) | 1999-05-17 | 2002-12-10 | Queen's University At Kingston | Method of inhibiting neurotrophin-receptor binding |
| US7148352B2 (en) | 1999-05-17 | 2006-12-12 | Queen's University At Kingston | Method of inhibiting neurotrophin-receptor binding |
| US7579468B2 (en) | 2005-09-15 | 2009-08-25 | Painceptor Pharma Corporation | Methods of modulating neurotrophin-mediated activity |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2728685A1 (en) | DRUG | |
| DE2043933C3 (en) | N- (ß-Naphthylaminomethyl) -aminocarboxylic acids and drugs containing them | |
| DE3112055A1 (en) | BISPIDINE DERIVATIVES, THEIR PRODUCTION AND THE MEDICINAL PRODUCTS CONTAINING THEM | |
| CH669523A5 (en) | ||
| DE2713103C2 (en) | 1-Nitro-9-dialkylaminisoalkylaminakridines, their salts and processes for their preparation | |
| DE60219963T2 (en) | PHARMACEUTICAL COMPOSITION USED FOR GLUCOSE CONTROL IN THE BLOOD OF PATIENTS WITH DIABETES TYPE 2 | |
| EP0374096B1 (en) | Combination therapy involving 2',3'-dideoxypurine nucleoside and an inhibitor of purine nucleoside phosphorylase, and its compositions | |
| DE3707652A1 (en) | Use of benzo[de]isoquinoline-1,3-diones for preparing pharmaceuticals | |
| WO1999000122A1 (en) | Method for reducing body weight | |
| DE3739779A1 (en) | PHARMACEUTICAL PRAEPARATE | |
| DE3141970C2 (en) | ||
| DE4014672A1 (en) | Adamantane derivs. for cyto-protection of cells - protects infected and non-infected lymphocytes and other cells, and can be used in treating e.g. AIDs and ARC | |
| EP0219728B1 (en) | Preparation on the basis of a mixture | |
| DE69533742T2 (en) | Use of proline and / or derivatives as anti-hepatitis agents | |
| DE2236876C3 (en) | N-substituted aminocarboxylic acids and medicaments containing these compounds | |
| EP0276369B1 (en) | Use of anipamil in the treatment of arteriosclerosis | |
| EP0489043B1 (en) | Use of the (+)-enantiomer of anipamil | |
| EP0278040A1 (en) | Use of pteridines and/or purines or of a xanthineoxidase inhibitor for the preparation of a medicament for the treatment of hereditary degenerative retinal diseases | |
| DE2438288A1 (en) | NEW ANTIARRHYTHMICS | |
| DE2823268C2 (en) | ||
| DE3315607A1 (en) | USE OF ALBENDAZOL IN ORAL ADMINISTRATION FOR CONTROLLING ECHINOCOCCOSIS OF MAN AND MEDICINAL PRODUCTS | |
| WO2014207187A1 (en) | Anti-virally effective pharmaceutical composition | |
| DE3017026A1 (en) | ISOPRENYLAMINE AND ITS ACID ADDITION SALTS AND ANTIVIRUS CONTAINERS THEREFORE FOR VERTEBLE ANIMALS | |
| DE2845762C2 (en) | ||
| EP0271591B1 (en) | Medicinal compound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8141 | Disposal/no request for examination |